PMID- 32162525
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20240425
IS  - 1938-2731 (Electronic)
IS  - 1533-3175 (Print)
IS  - 1533-3175 (Linking)
VI  - 35
DP  - 2020 Jan-Dec
TI  - Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM 
      Using FAERS.
PG  - 1533317519899546
LID - 10.1177/1533317519899546 [doi]
LID - 1533317519899546
AB  - Alzheimer disease (AD) may develop after the onset of type 2 diabetes mellitus 
      (T2DM), and the risk of AD may depend on the antidiabetic drug administered. We 
      compared the risk of AD among 66 085 patients (>/= 65 years) with T2DM (1250 having 
      concomitant AD) who had been administered antidiabetic drug monotherapy for T2DM 
      who had voluntarily reported themselves in the Food and Drug Administration 
      Adverse Event Reporting System. The risk of AD from the use of different 
      antidiabetic drug monotherapies compared to that of metformin monotherapy was 
      assessed by logistic regression. Rosiglitazone (adjusted reporting odds ratio 
      [aROR] = 0.11; 95% confidence interval [CI]: 0.07-0.17; P < .001), exenatide 
      (aROR = 0.22; 95% CI: 0.11-0.37; P < .001), liraglutide (aROR = 0.36; 95% CI: 
      0.19-0.62; P < .001), dulaglutide (aROR = 0.39; 95% CI: 0.17-0.77; P = .014), and 
      sitagliptin (aROR = 0.75; 95% CI: 0.60-0.93; P = .011) were found to have a 
      significantly lower associated risk of AD than that of metformin. Therefore, the 
      administration of glucagon-like peptide 1 receptor agonists and rosiglitazone may 
      reduce the risk of AD in patients with T2DM.
FAU - Akimoto, Hayato
AU  - Akimoto H
AUID- ORCID: 0000-0002-5397-0137
AD  - Faculty of Pharmacy and Pharmaceutical Sciences, Department of Analytical 
      Pharmaceutics and Informatics, Josai University, Sakado, Saitama, Japan.
FAU - Negishi, Akio
AU  - Negishi A
AD  - Faculty of Pharmacy and Pharmaceutical Sciences, Department of Analytical 
      Pharmaceutics and Informatics, Josai University, Sakado, Saitama, Japan.
FAU - Oshima, Shinji
AU  - Oshima S
AUID- ORCID: 0000-0003-2638-0550
AD  - Faculty of Pharmacy and Pharmaceutical Sciences, Department of Analytical 
      Pharmaceutics and Informatics, Josai University, Sakado, Saitama, Japan.
FAU - Wakiyama, Haruna
AU  - Wakiyama H
AD  - Faculty of Pharmacy and Pharmaceutical Sciences, Department of Analytical 
      Pharmaceutics and Informatics, Josai University, Sakado, Saitama, Japan.
FAU - Okita, Mitsuyoshi
AU  - Okita M
AD  - Josai University Pharmacy, Iruma-gun, Saitama, Japan.
FAU - Horii, Norimitsu
AU  - Horii N
AD  - Josai University Pharmacy, Iruma-gun, Saitama, Japan.
AD  - Faculty of Pharmacy and Pharmaceutical Sciences, Laboratory of Pharmacy 
      Management, Josai University, Sakado, Saitama, Japan.
FAU - Inoue, Naoko
AU  - Inoue N
AD  - Josai University Pharmacy, Iruma-gun, Saitama, Japan.
AD  - Faculty of Pharmacy and Pharmaceutical Sciences, Laboratory of Pharmacy 
      Management, Josai University, Sakado, Saitama, Japan.
FAU - Ohshima, Shigeru
AU  - Ohshima S
AD  - Josai University Pharmacy, Iruma-gun, Saitama, Japan.
AD  - Faculty of Pharmacy and Pharmaceutical Sciences, Laboratory of Pharmacy 
      Management, Josai University, Sakado, Saitama, Japan.
FAU - Kobayashi, Daisuke
AU  - Kobayashi D
AD  - Faculty of Pharmacy and Pharmaceutical Sciences, Department of Analytical 
      Pharmaceutics and Informatics, Josai University, Sakado, Saitama, Japan.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Alzheimers Dis Other Demen
JT  - American journal of Alzheimer's disease and other dementias
JID - 101082834
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Immunoglobulin Fc Fragments)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - 839I73S42A (Liraglutide)
RN  - 9100L32L2N (Metformin)
RN  - 9P1872D4OL (Exenatide)
RN  - WTT295HSY5 (dulaglutide)
SB  - IM
MH  - Aged
MH  - Alzheimer Disease/*diagnosis
MH  - Diabetes Mellitus, Type 2/*complications/drug therapy
MH  - Exenatide/therapeutic use
MH  - Female
MH  - Glucagon-Like Peptides/analogs & derivatives/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/*adverse effects
MH  - Immunoglobulin Fc Fragments/therapeutic use
MH  - Liraglutide/therapeutic use
MH  - Male
MH  - Metformin/*adverse effects/*therapeutic use
MH  - Recombinant Fusion Proteins/therapeutic use
PMC - PMC11005324
OTO - NOTNLM
OT  - Alzheimer disease
OT  - FDA adverse event reporting system
OT  - antidiabetics
OT  - dementia
OT  - type 2 diabetes mellitus
COIS- The authors declared no potential conflicts of interest with respect to the 
      research, authorship, and/or publication of this article.
EDAT- 2020/03/13 06:00
MHDA- 2020/12/15 06:00
PMCR- 2020/03/12
CRDT- 2020/03/13 06:00
PHST- 2020/03/13 06:00 [entrez]
PHST- 2020/03/13 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/03/12 00:00 [pmc-release]
AID - 10.1177_1533317519899546 [pii]
AID - 10.1177/1533317519899546 [doi]
PST - ppublish
SO  - Am J Alzheimers Dis Other Demen. 2020 Jan-Dec;35:1533317519899546. doi: 
      10.1177/1533317519899546.